InflaRx (IFRX) Market Capitalization (2017 - 2026)
InflaRx's (IFRX) quarterly Market Capitalization came in at $161.9 million in Q2 2026, up 245.37% year-over-year from $46.9 million in Q2 2025, and up 151.69% quarter-over-quarter from $64.3 million in Q1 2026.
Analysis
InflaRx (IFRX) Market Capitalization (2017 - 2026) Analysis & Trends
InflaRx has disclosed Market Capitalization across 10 years of filings, most recently posting $161.9 million for Q2 2026.
- In Q2 2026, Market Capitalization rose 245.37% year-over-year to $161.9 million; the TTM figure through Jun 2026 stood at $161.9 million (up 245.37% YoY), while the FY2025 annual figure was $73.0 million, down 50.19% from the prior year.
- Market Capitalization came in at $161.9 million for Q2 2026 at InflaRx, up from $64.3 million in the prior quarter.
- In the past five years, Market Capitalization ranged from a high of $199.4 million in Q2 2023 to a low of $46.9 million in Q2 2025.
- Average Market Capitalization over 5 years is $101.8 million, with a median of $90.4 million recorded in 2024.
- Year-over-year, Market Capitalization sank 54.24% in 2025 and soared 245.37% in 2026.
- Over 5 years, Market Capitalization stood at $138.6 million in 2022, then plunged by 30.74% to $96.0 million in 2023, then surged by 52.74% to $146.6 million in 2024, then tumbled by 50.19% to $73.0 million in 2025, then surged by 121.78% to $161.9 million in 2026.
- Per Business Quant data, the three most recent Market Capitalization figures were $161.9 million in Q2 2026, $64.3 million in Q1 2026, and $73.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 161.94 Mn |
| Mar 31, 2026 | 64.34 Mn |
| Dec 31, 2025 | 73.02 Mn |
| Sep 30, 2025 | 79.53 Mn |
| Jun 30, 2025 | 46.89 Mn |
| Mar 31, 2025 | 60.54 Mn |
| Dec 31, 2024 | 146.60 Mn |
| Sep 30, 2024 | 90.09 Mn |
| Jun 30, 2024 | 102.46 Mn |
| Mar 31, 2024 | 90.68 Mn |
| Dec 31, 2023 | 95.98 Mn |
| Sep 30, 2023 | 133.22 Mn |
| Jun 30, 2023 | 199.38 Mn |
| Mar 31, 2023 | 86.73 Mn |
| Dec 31, 2022 | 138.58 Mn |
| Sep 30, 2022 | 116.70 Mn |
| Jun 30, 2022 | 64.10 Mn |
| Mar 31, 2022 | 80.89 Mn |
| Dec 31, 2021 | 210.41 Mn |
| Sep 30, 2021 | 73.11 Mn |